U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    56,571.97
    +1,846.45 (+3.37%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

'Worst Looks Over' For Canopy Growth, Bank Of America Says In Upgrade

Canopy Growth Corp's (NYSE: CGC) shares have fallen 65% in the last six months. On Wednesday, the cannabis stock received an upgrade from Bank of America Merrill Lynch, which said Canopy is poised to meet Street expectations.

The Analyst

Christopher Carey upgraded Canopy Growth from Neutral to Buy with an unchanged CA$24 ($19) price objective.

The Thesis

Two months ago, Bank of America was "concerned" about the consensus sales estimates for Canopy, but that's no longer the case, Carey said in the Wednesday upgrade note. (See his track record here.)

The sell-side firm had lowered its rating on the stock at the time with the view that Street estimates for Canopy and its peers were too high given a temporary slowdown in cannabis orders across provinces, the analyst said.

Now, after considerable consensus cuts, Canopy estimates seem much more achievable, Carey said.

“Indeed, since our downgrade Sept 27, consensus revenues for the upcoming two quarters– FQ320 (CQ419) and FQ420 (CQ120) –have been cut 32/36%, while FY20/21 is -27/-32%.”

While things are not perfect at Canopy — and the company still has to prove itself — the worst seems to be over, and the market may reconsider Canopy’s potential, he said.

“Following results last week, we believe this dynamic is now well understood; with the stock -38% vs SPX +5%, valuation 7/5x CY20/21e sales, and estimates appearing achievable, we think risk-reward is sufficiently better to recommend buying shares.”

Price Action

Canopy shares were trading 11.29% higher at $17.05 at the time of publication Wednesday.

Related Links:

Canopy Growth Analysts Parse Q2 Print As Investors Retreat

Analyst: Canopy Growth Looks Greener Than It Did 6 Weeks Ago

Latest Ratings for CGC

Nov 2019

Upgrades

Neutral

Buy

Nov 2019

Maintains

Buy

Nov 2019

Downgrades

Buy

Hold

View More Analyst Ratings for CGC
View the Latest Analyst Ratings

0

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.